Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. URSOLVAN (acide ursodéoxycholique)
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

URSOLVAN (acide ursodéoxycholique)

Medicine - Posted on Jun 20 2018 - Updated on Jun 12 2019
Active substance (DCI)
  • acide ursodéoxycholique
history (4)
  • 5/30/18

    URSOLVAN (acide ursodéoxycholique)
    Maintien du remboursement dans les mêmes conditions.
    icône flèche
  • 3/16/16

    URSOLVAN (acide ursodéoxycholique)
    Extension de l'indication aux enfants âgés de 6 ans à moins de 18 ans
    CAV :
    54321
    icône flèche
  • 3/20/13

    URSOLVAN (acide ursodéoxycholique)
    URSOLVAN (acide ursodéoxycholique)
    icône flèche
  • 11/7/07

    URSOLVAN (acide ursodéoxycholique)
    URSOLVAN (acide ursodéoxycholique)
    icône flèche
Technical information
ATC code
  • A05AA02
Manufacturer
CHEPLAPHARM FRANCE/ SANOFI-AVENTIS FRANCE/ SERB
Presentation

URSOLVAN 200 mg, gélule (code CIS : 66830922)
B/30 - (Code CIP : 34009 323 407 5 0)

All our publications
    Congenital, genetic and rare diseases Drug therapy Liver diseases Paediatrics Pancreatic and biliary tract diseases Pulmonary and pleural diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
EZ48TNTThYk8B8AA